{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '2855 Gazelle Court',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 58.98,
 'askSize': 1000,
 'averageDailyVolume10Day': 561700,
 'averageVolume': 803061,
 'averageVolume10days': 561700,
 'beta': 1.636974,
 'beta3Year': None,
 'bid': 58.91,
 'bidSize': 800,
 'bookValue': 9.766,
 'category': None,
 'circulatingSupply': None,
 'city': 'Carlsbad',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 59.695,
 'dayLow': 58.08,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 34.17,
 'enterpriseToRevenue': 7.13,
 'enterpriseValue': 6835756544,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 59.770287,
 'fiftyTwoWeekHigh': 73.09,
 'fiftyTwoWeekLow': 39.32,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 132296480,
 'forwardEps': -0.2,
 'forwardPE': -294.75,
 'fromCurrency': None,
 'fullTimeEmployees': 817,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.050100002,
 'heldPercentInstitutions': 0.8793,
 'industry': 'Biotechnology',
 'isEsgPopulated': True,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ionispharma.com',
 'longBusinessSummary': 'Ionis Pharmaceuticals, Inc. discovers and develops '
                        'RNA-targeted therapeutics in the United States. The '
                        'company offers SPINRAZA for spinal muscular atrophy '
                        '(SMA) in pediatric and adult patients; and TEGSEDI, '
                        'an injection for the treatment of polyneuropathy of '
                        'hereditary transthyretin-mediated amyloidosis in '
                        'adults. It is involved in developing neurology '
                        "products that include IONIS-HTTRx for Huntington's "
                        'diseases; and IONIS-SOD1Rx and IONIS-C9Rx for '
                        'amyotrophic lateral sclerosis and IONIS-MAPTRx for '
                        "Alzheimer's diseases. The company is also developing "
                        'severe and rare disease products, such as WAYLIVRA, a '
                        'treatment for familial chylomicronemia syndrome; '
                        'WAYLIVRA, a treatment for familial partial '
                        'lipodystrophy; AKCEA-TTR-LRx for transthyretin '
                        'amyloidosis and IONIS-GHR-LRx for acromegaly; and '
                        'IONIS-TMPRSS6-LRx for beta-thalassemia and iron '
                        'toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary '
                        'angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. '
                        'In addition, its cardio metabolic and renal drugs '
                        'include AKCEA-ANGPTL3-LRx for cardio metabolic '
                        'disorders, IONIS-FXIRx for clotting disorders, '
                        'AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for '
                        'cardiovascular diseases, and IONIS-DGAT2Rx for '
                        'nonalcoholic steatohepatitis; IONIS-AGT-LRX for the '
                        'treatment of resistant hyper tension; and '
                        'IONIS-FXI-LRx for clotting disorders and '
                        'IONIS-AZ4-2.5-LRx for cardiovascular diseases. '
                        'Further, the company develops products for oncology '
                        'that include IONIS-AR-2.5Rx and danvatirsen for '
                        'cancers; and IONIS-HBVRx and IONIS-HBV-LRx for '
                        'hepatitis b virus infection, and IONIS-FB-LRx for '
                        'compliment meditated disease, and IONIS-JBI1-2.5Rx '
                        'for gastrointestinal autoimmune diseases. Ionis '
                        'Pharmaceuticals, Inc. was founded in 1989 and is '
                        'based in Carlsbad, California.',
 'longName': 'Ionis Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 8212972544,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_30300',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 160794000,
 'nextFiscalYearEnd': 1640908800,
 'open': 59.28,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -2.26,
 'phone': '760-931-9200',
 'previousClose': 59.7,
 'priceHint': 2,
 'priceToBook': 6.036248,
 'priceToSalesTrailing12Months': 8.566316,
 'profitMargins': 0.16841999,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 59.695,
 'regularMarketDayLow': 58.08,
 'regularMarketOpen': 59.28,
 'regularMarketPreviousClose': 59.7,
 'regularMarketPrice': 59.28,
 'regularMarketVolume': 469176,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 139320992,
 'sharesPercentSharesOut': 0.062,
 'sharesShort': 8631831,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8808012,
 'shortName': 'Ionis Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.073699996,
 'shortRatio': 9.82,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'IONS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.128,
 'trailingPE': 52.26064,
 'twoHundredDayAverage': 56.240288,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'e2f8b663-1b31-3cee-8363-06c9dcf00fd4',
 'volume': 469176,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ionispharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92010'}